Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFPP-derived Antibodies for Critical COVID-19
NCT04346589Terminated
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Apr 2020
- Primary completion
- Feb 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of anti-SARS-CoV-2 convalescent antibodies in COVID-19 pneumonia, sponsored by Papa Giovanni XXIII Hospital. Primary endpoint: Number of mechanical ventilation days at 6 months. Started Apr 2020; status: terminated.
02
Drugs
anti-SARS-CoV-2 convalescent antibodies
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04346589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04346589.